Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
Department of Radiology, All India Institute of Medical Sciences, New Delhi, India.
Indian J Dermatol Venereol Leprol. 2019 Jan-Feb;85(1):44-50. doi: 10.4103/ijdvl.IJDVL_760_17.
Available options for correction of facial volume loss, such as synthetic fillers, autologous fat and cultured fibroblasts, have limitations viz. temporary effect and high cost.
To assess the use of a novel technique, autologous non-cultured dermal cell suspension transplantation, for correction of localized facial volume loss due to inflammatory pathologies.
It was a pilot study conducted in the Dermatology Outpatient Department, All India Institute of Medical Sciences (AIIMS), New Delhi, India. Autologous non-cultured dermal cell suspension was transplanted in a total of 10 patients, out of which 5 had predominantly dermal loss and the rest had predominantly lipoatrophy. The donor tissue from the gluteal region was digested into a single cell suspension using collagenase-1 and injected into the recipient area. The outcome was assessed subjectively by patients and investigators and objectively using ultrasonography. Cell count, viability testing and measurement of mesenchymal stem cells were also done.
On assessment of patients, the median improvement in the predominantly dermal atrophy group at 3 and 6 months was 70% (range: 10-90%) and 80% (range: 0-90%), respectively, and in the predominantly lipoatrophy group, 0% (range: 0-40) and 0% (range: 0-50), respectively. Mean thickness of dermis + subcutis at the baseline was 1.835 mm (range: 0.89-6.04 mm), which increased to 2.912 mm (range: 0.88-7.07 mm, P = 0.03) at 6 months.
Our pilot study has some limitations such as small sample size and heterogeneity of the recruited patients.
Autologous non-cultured dermal cell suspension transplantation appears to be safe and effective in localized facial dermal defects because of inflammatory pathologies, but not effective in deeper defects.
现有的面部容量缺失矫正方法，如合成填充物、自体脂肪和培养的成纤维细胞等，都存在一些局限性，例如效果短暂和成本高昂。
评估一种新的技术，即自体非培养真皮细胞悬液移植，用于矫正因炎症性病变导致的局部面部容量缺失。
这是在印度新德里全印度医学科学研究所（AIIMS）皮肤科门诊进行的一项试点研究。共对 10 名患者进行了自体非培养真皮细胞悬液移植，其中 5 名患者主要为真皮缺失，其余患者主要为脂肪萎缩。使用胶原酶-1将来自臀部的供体组织消化成单细胞悬液，并注射到受体区域。通过患者和研究者的主观评估以及超声检查的客观评估来评估结果。还进行了细胞计数、活力测试和间充质干细胞测量。
在评估患者时，主要为真皮萎缩组在 3 个月和 6 个月时的中位数改善分别为 70%（范围：10-90%）和 80%（范围：0-90%），而主要为脂肪萎缩组的改善分别为 0%（范围：0-40%）和 0%（范围：0-50%）。基线时真皮+皮下组织的平均厚度为 1.835 毫米（范围：0.89-6.04 毫米），在 6 个月时增加到 2.912 毫米（范围：0.88-7.07 毫米，P=0.03）。
我们的试点研究存在一些局限性，例如样本量小和招募患者的异质性。
自体非培养真皮细胞悬液移植似乎安全有效，可用于因炎症性病变导致的局部面部真皮缺陷，但对更深层的缺陷无效。
